Whole-body magnetic resonance imaging (WB-MRI) is being employed with increasing frequency to evaluate a broader spectrum of patients with diverse types of cancer and for cancer screening purposes. While clinical guidelines support its use, a standardized radiological approach is still lacking. To improve consistency in the acquisition, interpretation, and reporting of WB-MRI examinations, three reporting and data systems (RADSs) have been recently suggested: METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P), Myeloma Response Assessment and Diagnosis System (MY-RADS), and Oncologically Relevant Findings Reporting and Data System (ONCO-RADS). MET-RADS-P was developed to stage and monitor men with advanced prostate cancer using WB-MRI. It has emerged as a reliable imaging biomarker for predicting metastatic disease progression and assessing treatment response. MY-RADS was developed to stage and monitor patients with multiple myeloma using WB-MRI, emerging as a prognostic imaging biomarker. However, the evidence regarding inter-reader agreement for MY-RADS is currently limited. ONCO-RADS was developed to standardize the use of WB-MRI for cancer screening in individuals with cancer predisposition syndromes and in the general population. While initial findings are promising, the evidence supporting its use remains limited. To further validate and expand upon these promising preliminary findings, additional large-scale, prospective, multicenter studies are necessary.
全身磁共振成像（WB-MRI）正被越来越多地用于评估更广泛类型的癌症患者以及用于癌症筛查目的。尽管临床指南支持其应用，但目前仍缺乏标准化的影像学方法。为提高WB-MRI检查在图像采集、解读和报告方面的一致性，近期提出了三种报告与数据系统：前列腺癌转移报告与数据系统（MET-RADS-P）、多发性骨髓瘤疗效评估与诊断系统（MY-RADS）以及肿瘤相关发现报告与数据系统（ONCO-RADS）。MET-RADS-P旨在通过WB-MRI对晚期前列腺癌患者进行分期和监测，已成为预测转移性疾病进展和评估治疗反应的可靠影像学生物标志物。MY-RADS则用于通过WB-MRI对多发性骨髓瘤患者进行分期和监测，并显示出作为预后影像学生物标志物的潜力，但目前关于其阅片者间一致性的证据仍有限。ONCO-RADS旨在标准化WB-MRI在癌症易感综合征患者及普通人群癌症筛查中的应用，初步研究结果虽具前景，但支持其应用的证据尚不充分。为进一步验证并拓展这些有前景的初步发现，有必要开展更多大规模、前瞻性、多中心研究。
肿瘤(癌症)患者之家